in BRCA-deficient tumors. Here we report the AI-enabled development of 3-hydroxymethyl-azetidine derivatives as a novel class of Pol inhibitors featuring central scaffolding rings. Structure-based drug design first identified as a lead compound, which was further optimized to the more potent derivative and the metabolically stable deuterated compound exhibited significant antiproliferative properties
低保真度
DNA 聚合酶 Theta (Pol) 的抑制正在成为 BRCA 缺陷肿瘤中一种有吸引力的合成致死抗肿瘤策略。在这里,我们报告了人工智能开发的 3-羟甲基-氮杂
环丁烷衍
生物,作为一类具有中心支架环的新型 Pol
抑制剂。基于结构的药物设计首先确定为先导化合物,并进一步优化为更有效的衍
生物,代谢稳定的
氘化化合物在 DNA 修复受损的细胞中表现出显着的抗增殖特性,并表现出良好的药代动力学,表明 3-羟甲基-氮杂
环丁烷是
吡咯烷-3-醇的有效
生物等排体,并强调人工智能在药物
化学中精确分子修饰的潜力。